To the content

Information or Pharmaceutical Advertising? German Federal Court of Justice Sets Limits for Digital Healthcare Platforms

The German Federal Court of Justice has ruled that advertising by a platform arranging medical treatment may violate the prohibition on advertising prescription-only medicinal products to the general public. It is not decisive whether the platform itself manufactures or sells medicinal products. The overall impression created by its online presence is what matters.

Although the case concerned medical cannabis, its significance extends well beyond the cannabis market.

Arranging treatments involving medical cannabis

The defendant operated an online platform through which interested individuals could book appointments with private-practice doctors for treatments involving medical cannabis. The platform received remuneration from the participating doctors for its services.

The same corporate group also included a pharmaceutical wholesaler specialising in the import and distribution of medical cannabis and a company operating a marketplace for mail-order pharmacies specialising in cannabis products.

Certain pages of the platform’s website described medical cannabis and its potential use for various health conditions. Users were then able to submit treatment requests to cooperating doctors.

The German Centre for Protection against Unfair Competition considered the website to constitute unlawful advertising of prescription-only medicinal products to the public.

The Federal Court confirmed a violation of section 10 HWG

The German Federal Court of Justice upheld the judgment of the Frankfurt am Main Higher Regional Court and dismissed the platform operator’s appeal.

Under section 10(1) of the German Healthcare Advertising Act (Heilmittelwerbegesetz – HWG), prescription-only medicinal products may generally be advertised only to doctors, dentists, veterinarians, pharmacists and certain other professional groups. Advertising such products to the general public is prohibited.

Medical cannabis is a prescription-only medicinal product under the German Medical Cannabis Act. The Federal Court classified the website content in question as advertising for such a medicinal product.

No specific brand or manufacturer needs to be named

The platform had not referred to a particular cannabis product or manufacturer. However, that did not prevent the content from being classified as pharmaceutical advertising.

According to the Court, advertising may also relate to an entire class of prescription-only medicinal products. It is sufficient for that class to be identifiable with adequate specificity.

The platform had not limited itself to an abstract description of an active substance or neutral information about the regulatory framework. It expressly referred to medical cannabis and described its use in connection with particular health conditions.

The subject matter of the advertising was therefore sufficiently identifiable.

The doctor’s prescribing authority does not protect the platform

The platform argued, among other things, that the decision whether to issue a prescription remained exclusively with the treating doctor.

In the Court’s view, this did not prevent the website from constituting pharmaceutical advertising. One of the purposes of section 10(1) HWG is to prevent consumers from being induced by advertising to pressure a doctor into prescribing a particular prescription-only medicinal product or class of products.

The involvement of a doctor therefore does not automatically remove the advertising from the scope of the HWG.

Permissible information or sales-promoting advertising?

The distinction between neutral health information and sales-promoting advertising is particularly important.

Objective and balanced information about illnesses and different treatment options may generally be permissible. Communication becomes problematic where it presents the benefits of one particular medicinal product or class of medicinal products in isolation and directs users immediately towards obtaining that treatment.

The Federal Court found that the platform had presented the benefits of cannabis treatment in an isolated manner. Based on their overall impression, the relevant webpages were designed to promote the sale of medical cannabis.

The content therefore went beyond appropriate and comprehensive information about available treatment options.

The platform’s economic interest as a relevant factor

The platform’s business model may also be relevant to the legal assessment.

The defendant received remuneration for referring patients to doctors. It also had corporate links to businesses operating in cannabis wholesale distribution and the pharmacy market.

Such connections do not automatically make a service unlawful. They may, however, be relevant when assessing the overall impression and commercial purpose of the communication.

Companies should therefore not examine individual statements in isolation. User journeys, remuneration structures, corporate relationships and connections with manufacturers, wholesalers, doctors or pharmacies may all influence the legal assessment.

Significance beyond the cannabis market

The decision is relevant to numerous digital business models in the healthcare sector, including

  • telemedicine platforms;
  • portals arranging medical treatment;
  • digital pharmacy platforms;
  • manufacturer websites offering doctor-finder services;
  • suppliers of prescription-only medicinal products;
  • platforms offering weight-loss or hormone treatments; and
  • digital services in pain management, dermatology or sexual health.

A particular risk arises where a business describes certain symptoms, highlights a specific prescription-only treatment and then directs users immediately to a cooperating doctor or pharmacy.

What companies should review

Companies should not assess their digital content solely on the basis of individual phrases. The entire user journey must be reviewed.

Relevant questions include:

  • Are different treatment options presented in a balanced manner?
  • Is a particular prescription-only product or product category highlighted?
  • Are specific indications or conditions identified?
  • Can users immediately request the corresponding treatment?
  • Are there financial or corporate connections with doctors, pharmacies, wholesalers or manufacturers?
  • Does the platform receive success-based or treatment-related remuneration?
  • Does the website appear to provide neutral information while in fact pursuing sales-promoting objectives?
  • Are editorial information and commercial services adequately separated?

Search engine advertising, social media campaigns, influencer partnerships and automated symptom or treatment finders must also be included in the compliance review.

Conclusion

The German Federal Court of Justice has made clear that digital healthcare platforms cannot avoid healthcare advertising law merely by describing themselves as intermediaries or information providers.

Advertising to the public may be unlawful even where no particular manufacturer or branded product is named. The decisive question is whether the website, viewed as a whole, is intended to promote an identifiable category of prescription-only medicinal products.

Businesses operating in the digital healthcare market should therefore review their content, user journeys and economic model together. The dividing line between permissible information and prohibited pharmaceutical advertising does not depend on individual terms, but on the overall effect of the service.

Case reference: German Federal Court of Justice, judgment of 26 March 2026 – I ZR 74/25; preceding decisions: Frankfurt am Main Higher Regional Court, judgment of 6 March 2025 – 6 U 74/24; Frankfurt am Main Regional Court, judgment of 27 February 2024 – 3-08 O 540/23.

This article provides general information only and does not constitute legal advice in any individual case.

https://www.bundesgerichtshof.de/SharedDocs/Pressemitteilungen/DE/2026/2026055.